Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Myasthenia Gravis Clinical Trials

93 recruiting trials for Myasthenia Gravis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
93
Total Trials
93
Recruiting Now
15
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGNCT06940323

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

PRISMA, is a pregnancy registry study, focused on comprehensively collecting information about pregnancy in women with chronic neurological conditions from across the United...

Sponsor: University of California, San FranciscoEnrolling: 2501 location
RECRUITINGPhase 1NCT06249438

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients...

Sponsor: RenJi HospitalEnrolling: 301 location
RECRUITINGNCT07136844

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases...

Sponsor: Centre Hospitalier Universitaire de LiegeEnrolling: 3001 location
RECRUITINGNCT06539169

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in...

Sponsor: xCuresEnrolling: 10001 location
RECRUITINGPhase 3NCT06463587

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized...

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in...

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyEnrolling: 26420 locations
RECRUITINGNCT07146425

Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis

This research is a single-center, exploratory, observational study to be carried out in the outpatient or inpatient ward of the Neurology Department at Huashan Hospital,...

Sponsor: Huashan HospitalEnrolling: 1801 location
RECRUITINGNCT06617741

Myasthenia Gravis Foundation of America Global MG Patient Registry

The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are:...

Sponsor: Myasthenia Gravis Foundation of AmericaEnrolling: 38001 location
RECRUITINGNCT06064695

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on neuromuscular junction (NMJ)...

Sponsor: University of Missouri-ColumbiaEnrolling: 162 locations
RECRUITINGPhase 3NCT06765161

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will...

Sponsor: Clinique Neuro-OutaouaisEnrolling: 301 location
RECRUITINGPhase 2NCT06987539

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With...

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and...

Sponsor: AmgenEnrolling: 151 location
RECRUITINGPhase 1 / Phase 2NCT06704269

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a...

Sponsor: Novartis PharmaceuticalsEnrolling: 1510 locations
RECRUITINGPhase 1NCT06680037

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).

Sponsor: TG Therapeutics, Inc.Enrolling: 328 locations
RECRUITINGNCT06299748

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod...

This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod or efgartigimod PH20 SC any time within 25 days prior to conception or any time during...

Sponsor: argenxEnrolling: 2794 locations
RECRUITINGNCT06754020

TCM Tongue Diagnosis and Syndrome Differentiation in Myasthenia Gravis Compared to Healthy Controls

Myasthenia gravis primarily results from neuromuscular junction dysfunction and damage, leading to chronic muscle weakness. While combined traditional and Western medicine...

Sponsor: Yi Ting YehEnrolling: 1001 location
RECRUITINGNCT05337891

Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis

Myasthenia gravis (MG) is the autoimmune disorder affecting the neuromuscular junction, characterized by fatigue, which increases gradually through the day. The repetitive nerve...

Sponsor: Jagiellonian UniversityEnrolling: 401 location
RECRUITINGPhase 3NCT06456580

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Sponsor: Vor BiopharmaEnrolling: 18020 locations
RECRUITINGPhase 1NCT06688435

A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized...

This study is a single-arm, open, 2-stage (dose-escalation phase and dose-expansion phase), multi-center, phase I clinical trial to evaluate the safety and tolerance of SYS6020...

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Enrolling: 501 location
RECRUITINGPhase 4NCT07072988

Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC...

Generalized Myasthenia Gravis (gMG) is a rare chronic autoimmune disorder causing muscle weakness and fatigue, primarily due to autoantibodies that disrupt neuromuscular junction...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 501 location
RECRUITINGNCT06743490

Capturing Key MG-symptoms Using Smartphone Recordings.

This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine...

Sponsor: Leiden University Medical CenterEnrolling: 2252 locations
RECRUITINGNCT07411963

Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis

Myasthenia Gravis (MG) is a rare autoimmune disease that causes muscle weakness and fatigue. It occurs when the immune system produces antibodies that block communication between...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 301 location
RECRUITINGNCT04837625

Study of Myasthenic Crisis in China

This study is a multicenter, prospective, observational research. It will register the basic demographic information, medical history characteristics, clinical features, auxiliary...

Sponsor: Huashan HospitalEnrolling: 3001 location
RECRUITINGPhase 3NCT06342544

Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter...

Myasthenia is an autoimmune disease causing dysfunction of the neuromuscular junction, resulting in fluctuating and variable muscle weakness. In the initial phase of the disease,...

Sponsor: Fondation Ophtalmologique Adolphe de RothschildEnrolling: 12811 locations
RECRUITINGNCT06455709

Markers of Favorable Response to Complement Inhibitors Therapy

Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction....

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 501 location
RECRUITINGNCT06685055

Markers of Favorable Response to FcRn Inhibitors(INFORM)

Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction....

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 501 location
RECRUITINGPhase 2 / Phase 3NCT06392386

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric...

Sponsor: argenxEnrolling: 1220 locations
RECRUITINGPhase 3NCT06517758

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants...

The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG...

Sponsor: Novartis PharmaceuticalsEnrolling: 14620 locations
RECRUITINGPhase 1 / Phase 2NCT07022197

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen...

Sponsor: Tianjin Medical University General HospitalEnrolling: 271 location
RECRUITINGNCT06241521

Myasthenia Gravis Registry in China

Myasthenia gravis (MG) is an autoimmune disease caused by dysfunction at the neuromuscular junction, characterized by partial or generalized skeletal muscle weakness and...

Sponsor: Huashan HospitalEnrolling: 150016 locations
RECRUITINGPhase 3NCT06799247

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor...

Sponsor: Cartesian TherapeuticsEnrolling: 10020 locations
RECRUITINGNCT05214612

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG....

Sponsor: Assiut UniversityEnrolling: 301 location
RECRUITINGPhase 1NCT06626919

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related...

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG)....

Sponsor: Arcellx, Inc.Enrolling: 3013 locations
RECRUITINGPhase 2 / Phase 3NCT06055959

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study...

Sponsor: UCB Biopharma SRLEnrolling: 89 locations
RECRUITINGPhase 3NCT07249632

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular...

Sponsor: RemeGen Co., Ltd.Enrolling: 1201 location
RECRUITINGEarly Phase 1NCT07058298

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the...

Sponsor: Daishi TianEnrolling: 61 location
RECRUITINGPhase 4NCT06909214

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia...

The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to...

Sponsor: argenxEnrolling: 3018 locations
RECRUITINGNCT06312644

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 758 locations
RECRUITINGPhase 2NCT07284420

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With...

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work...

Sponsor: argenxEnrolling: 705 locations
RECRUITINGNCT04182984

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk...

Sponsor: Tang-Du HospitalEnrolling: 2001 location
RECRUITINGPhase 1NCT06371040

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of CD19-BCMA CAR-T in the treatment of...

Sponsor: Ting Chang, MDEnrolling: 91 location
RECRUITINGPhase 1 / Phase 2NCT06106672

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.

Sponsor: COUR Pharmaceutical Development Company, Inc.Enrolling: 5417 locations
RECRUITINGNCT06815133

Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 Months

This study called "Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients with Anti-AChR...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 551 location
RECRUITINGNCT04202341

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 50020 locations
RECRUITINGPhase 2NCT05067348

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.

Sponsor: Tang-Du HospitalEnrolling: 646 locations
RECRUITINGPhase 2 / Phase 3NCT05265273

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\<) 18 years of age (globally)...

Sponsor: Janssen Research & Development, LLCEnrolling: 1219 locations
RECRUITINGPhase 1NCT06220201

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing...

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS),...

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 12020 locations
RECRUITINGNCT06909253

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Sponsor: AstraZenecaEnrolling: 5014 locations
RECRUITINGPhase 3NCT06607627

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 1213 locations
RECRUITINGNCT06879210

Application of Artificial Intelligence in Precision Medicine and Healthcare

This study aims to propose an intelligent health robot that utilizes remote intelligent robots to assist patients with disease-related issues, enabling them to address their...

Sponsor: Yi Ting YehEnrolling: 101 location
RECRUITINGNCT06659627

Interventions Against Fatigue in Patients With Myasthenia Gravis

A prospective assessor-blinded randomized clinical trial investigating the effect of aerobic exercise therapy or cognitive behavioural therapy on fatigue in patients with...

Sponsor: Leiden University Medical CenterEnrolling: 601 location

Showing 50 of 93 trials.Search all Myasthenia Gravis trials